CL2017001117A1 - Métodos para tratar enfermedades oculares. - Google Patents

Métodos para tratar enfermedades oculares.

Info

Publication number
CL2017001117A1
CL2017001117A1 CL2017001117A CL2017001117A CL2017001117A1 CL 2017001117 A1 CL2017001117 A1 CL 2017001117A1 CL 2017001117 A CL2017001117 A CL 2017001117A CL 2017001117 A CL2017001117 A CL 2017001117A CL 2017001117 A1 CL2017001117 A1 CL 2017001117A1
Authority
CL
Chile
Prior art keywords
methods
eye diseases
treat eye
treat
distration
Prior art date
Application number
CL2017001117A
Other languages
English (en)
Inventor
Peter Sallstig
Werner Schmidt
Margarita Gekkieva
James Warburton
Andreas Weichselberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001117A1 publication Critical patent/CL2017001117A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>SE PROPORCIONA UN MÉTODO PARA REDUCIR LA CARGA DEL TRATAMIENTO PARA PACIENTES QUE PADECEN UN TRASTORNO NEOVASCULAR INTRAOCULAR, DONDE EL MÉTODO COMPRENDE ADMINISTRAR UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DEL ANTAGONISTA DEL VEGF EN UNA ADMINISTRACIÓN DE LA DOSIFICACIÓN QUE INCLUYE INTERVALOS DE TRATAMIENTO DO 8 Y/O 12 SEMANAS.</p>
CL2017001117A 2014-11-07 2017-05-05 Métodos para tratar enfermedades oculares. CL2017001117A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
CL2017001117A1 true CL2017001117A1 (es) 2018-01-26

Family

ID=54697654

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001117A CL2017001117A1 (es) 2014-11-07 2017-05-05 Métodos para tratar enfermedades oculares.
CL2017001115A CL2017001115A1 (es) 2014-11-07 2017-05-05 Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017001115A CL2017001115A1 (es) 2014-11-07 2017-05-05 Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.

Country Status (24)

Country Link
US (5) US10689438B2 (es)
EP (2) EP3215122A1 (es)
JP (5) JP6667519B2 (es)
KR (3) KR20230066649A (es)
CN (3) CN106999581A (es)
AU (6) AU2015342818B2 (es)
BR (2) BR112017008660A2 (es)
CA (2) CA2966758A1 (es)
CL (2) CL2017001117A1 (es)
CO (1) CO2017004596A2 (es)
EA (1) EA201790989A1 (es)
EC (1) ECSP17034829A (es)
GT (1) GT201700096A (es)
IL (5) IL251642B (es)
MX (3) MX2017005875A (es)
MY (2) MY193913A (es)
NZ (1) NZ730821A (es)
PE (1) PE20170780A1 (es)
PH (2) PH12017500843A1 (es)
RU (1) RU2722643C2 (es)
SG (3) SG11201702909QA (es)
TN (1) TN2017000128A1 (es)
TW (4) TWI761959B (es)
WO (2) WO2016073915A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
SG10201802789VA (en) 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
BR112014008819A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Métodos para o tratamento de síndrome de vazamento vascular e câncer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
MX2019000727A (es) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Anticuerpos monoclonales humanizados que tienen como blanco ve-ptp (hptp-b).
WO2018046997A2 (en) * 2016-09-07 2018-03-15 Saksin Lifesciences Pvt Ltd Synthetic antibodies against vegf and their uses
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
UA126388C2 (uk) 2016-11-18 2022-09-28 Астеллас Фарма Інк. Fab-фрагмент антитіла до muc1 людини
JP2020513832A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
BR112020006434A2 (pt) 2017-10-06 2020-11-03 Prothena Biosciences Limited anticorpos anti-transtirretina
CU20200042A7 (es) * 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
IL276383B2 (en) * 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
EP3765083A1 (en) * 2018-03-16 2021-01-20 Novartis Ag Methods for treating ocular diseases
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ−β（ＶＥ−ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN112839683B (zh) * 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
CA3114728C (en) * 2018-10-29 2024-05-14 F. Hoffmann-La Roche Ag Antibody formulation
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
US11945859B2 (en) * 2018-12-18 2024-04-02 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂
EP3844169A4 (en) 2019-08-16 2021-12-15 Applied Molecular Transport Inc. COMPOSITIONS, FORMULATIONS AND PRODUCTION AND PURIFICATION OF INTERLEUKINS
EP4041312A4 (en) * 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN111217834B (zh) 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
CN113698478A (zh) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
PE20231093A1 (es) 2020-07-16 2023-07-18 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
AU2022275786A1 (en) * 2021-05-17 2023-04-06 Bayer Healthcare Llc Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2024056058A1 (zh) * 2022-09-16 2024-03-21 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
JP5216002B2 (ja) * 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
EP2304033B1 (en) 2008-06-30 2016-09-07 ESBATech, an Alcon Biomedical Research Unit LLC Functionalized polypeptides
SG10201802789VA (en) * 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
JP2014522843A (ja) * 2011-06-30 2014-09-08 ジェネンテック， インコーポレイテッド 抗ｃ−ｍｅｔ抗体製剤
ES2687245T3 (es) * 2011-10-20 2018-10-24 Esbatech - A Novartis Company Llc Anticuerpo estable de unión a antígenos múltiples
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
TWI761959B (zh) 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
IL283561B (en) 2022-01-01
IL251642A0 (en) 2017-06-29
PH12017500844A1 (en) 2017-10-30
TWI806150B (zh) 2023-06-21
CN114081951A (zh) 2022-02-25
US20180298092A1 (en) 2018-10-18
JP6667519B2 (ja) 2020-03-18
IL283561A (en) 2021-07-29
MY193913A (en) 2022-11-01
EA201790989A1 (ru) 2017-09-29
CA2966758A1 (en) 2016-05-12
US20160130337A1 (en) 2016-05-12
BR112017008660A2 (pt) 2017-12-26
MY183807A (en) 2021-03-16
MX2017005874A (es) 2017-06-26
RU2020114917A3 (es) 2022-01-17
IL280087B (en) 2022-02-01
US20210340242A1 (en) 2021-11-04
EP3215123A1 (en) 2017-09-13
ECSP17034829A (es) 2019-02-28
PH12017500843A1 (en) 2017-10-30
RU2017119647A (ru) 2018-12-07
SG11201702954XA (en) 2017-05-30
JP2020193212A (ja) 2020-12-03
IL251642B (en) 2021-02-28
US10035850B2 (en) 2018-07-31
IL280087A (en) 2021-03-01
AU2015342818B2 (en) 2019-01-03
WO2016073918A1 (en) 2016-05-12
AU2018278870A1 (en) 2019-01-03
CL2017001115A1 (es) 2018-01-26
RU2722643C2 (ru) 2020-06-02
JP2017534638A (ja) 2017-11-24
IL251696A0 (en) 2017-06-29
NZ730821A (en) 2019-11-29
KR20230066649A (ko) 2023-05-16
TWI761959B (zh) 2022-04-21
US20200270336A1 (en) 2020-08-27
US20160340420A1 (en) 2016-11-24
TW202103735A (zh) 2021-02-01
TW201625221A (zh) 2016-07-16
CO2017004596A2 (es) 2017-08-31
PH12017500844B1 (en) 2017-10-30
KR102588846B1 (ko) 2023-10-16
JP6753848B2 (ja) 2020-09-09
AU2020244614A1 (en) 2020-11-05
KR20170082526A (ko) 2017-07-14
AU2020244614B2 (en) 2023-06-01
WO2016073915A1 (en) 2016-05-12
TWI738632B (zh) 2021-09-11
AU2018274882A1 (en) 2018-12-20
SG10201913565RA (en) 2020-02-27
GT201700096A (es) 2019-10-10
JP2017538674A (ja) 2017-12-28
JP7080263B2 (ja) 2022-06-03
TW201625306A (zh) 2016-07-16
BR112017008093A2 (pt) 2018-03-13
TN2017000128A1 (en) 2018-10-19
CA2966646A1 (en) 2016-05-12
KR20170076781A (ko) 2017-07-04
AU2018274882B2 (en) 2020-07-09
CN106999581A (zh) 2017-08-01
US11098110B2 (en) 2021-08-24
MX2021006768A (es) 2021-07-15
AU2020220210B2 (en) 2022-01-20
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
JP2022141923A (ja) 2022-09-29
TWI705827B (zh) 2020-10-01
PE20170780A1 (es) 2017-07-04
MX2017005875A (es) 2017-06-26
TW202146049A (zh) 2021-12-16
RU2017119647A3 (es) 2019-05-29
AU2018278870B2 (en) 2020-05-28
RU2020114917A (ru) 2020-05-22
CN107635580A (zh) 2018-01-26
AU2015342815A1 (en) 2017-05-11
IL265497A (en) 2019-05-30
IL265497B (en) 2021-06-30
AU2020220210A1 (en) 2020-10-01
EP3215122A1 (en) 2017-09-13
JP2020079242A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
CL2017001117A1 (es) Métodos para tratar enfermedades oculares.
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
CL2017002242A1 (es) Método para tratar un tumor cerebral
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
AR101740A1 (es) Terapia de combinación y composiciones
EA201791199A1 (ru) Способ лечения болезни альцгеймера
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
AR102494A1 (es) Métodos para tratar enfermedades oculares
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
MX2022002947A (es) Avocatina b para el tratamiento de enfermedades y afecciones.
UA125566U (uk) Спосіб лікування хворих на феліноз
UA124910U (uk) Спосіб лікування когнітивних порушень при дисциркуляторній енцефалопатії в постменопаузі
UA97018U (uk) Спосіб лікування урогенітальних інфекцій у жінок з порушенням репродуктивної функції
UA98640U (ru) Способ лечения генерализованного тревожного расстройства с преобладанием соматовегетативного компонента тревоги у пожилых людей
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця